Loading clinical trials...
Loading clinical trials...
to Evaluate SCT510 Compared to Avasitin Respectively Combined Paclitaxel and Carboplatin First-line Treatment of Locally Advanced and Metastatic or Recurrent Squamous Cell Non-small Cell Lung Cancer Efficacy and Safety
Conditions
Interventions
SCT510
Bevacizumab
+2 more
Start Date
February 1, 2019
Primary Completion Date
May 1, 2021
Completion Date
January 1, 2022
Last Updated
January 3, 2019
NCT01673867
NCT04439890
Lead Sponsor
Sinocelltech Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions